Menu
Back to User profile » Dr Yongfang Yuan
Papers published by Dr Yongfang Yuan:
Treatment Adherence to Nucleos(t)ide Analogs in Chinese Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma: A Single-Center Cross-Sectional Study
Li Y, Chen A, Wang H, Han L, Wang R, Zhang G, Yuan Y
Patient Preference and Adherence 2021, 15:1729-1738
Published Date: 10 August 2021
Improving Solubility and Bioavailability of Breviscapine with Mesoporous Silica Nanoparticles Prepared Using Ultrasound-Assisted Solution-Enhanced Dispersion by Supercritical Fluids Method
Yang G, Li Z, Wu F, Chen M, Wang R, Zhu H, Li Q, Yuan Y
International Journal of Nanomedicine 2020, 15:1661-1675
Published Date: 10 March 2020
Salvianolic acid A attenuates CCl4-induced liver fibrosis by regulating the PI3K/AKT/mTOR, Bcl-2/Bax and caspase-3/cleaved caspase-3 signaling pathways
Wang R, Song F, Li S, Wu B, Gu Y, Yuan Y
Drug Design, Development and Therapy 2019, 13:1889-1900
Published Date: 31 May 2019
Formulation design, characterization, and in vitro and in vivo evaluation of nanostructured lipid carriers containing a bile salt for oral delivery of gypenosides
Yang G, Wu F, Chen M, Jin J, Wang R, Yuan Y
International Journal of Nanomedicine 2019, 14:2267-2280
Published Date: 1 April 2019
Tanshinol ameliorates CCl4-induced liver fibrosis in rats through the regulation of Nrf2/HO-1 and NF-κB/IκBα signaling pathway
Wang R, Wang J, Song F, Li S, Yuan Y
Drug Design, Development and Therapy 2018, 12:1281-1292
Published Date: 17 May 2018
Ginkgo biloba extract mitigates liver fibrosis and apoptosis by regulating p38 MAPK, NF-κB/IκBα, and Bcl-2/Bax signaling
Wang YY, Wang R, Wang YJ, Peng RQ, Wu Y, Yuan YF
Drug Design, Development and Therapy 2015, 9:6303-6317
Published Date: 3 December 2015